Xenitra LimitedASX: XEN

JD Health Strategic Agreement targeting $100m in Sales

· Issued by Xenitra Limited via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Xenitra Limited has announced a Strategic Cooperation Agreement with JD Health, targeting significant sales over three years for various pharmaceutical products, including prescription and over-the-counter medicines. This agreement represents a major strategic move into higher-margin products and is expected to enhance Xenitra's market presence in China's pharmaceutical sector. The partnership aims to leverage Xenitra's existing distribution channels and expertise to achieve the sales target.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement JD Health Strategic Agreement targeting $100m in Sales 18 November 2026, Beijing, China. Xenitra Limited (ASX:XEN) (Xenitra or the Company) is pleased to announce that Hong Kong Fukang Trading Co., Limited (Fukang), Xenitra’s pharmaceutical licensing and operating arm, through...

Xenitra Limited on 6ix

Earlier from Xenitra

All Xenitra news releases